METHODS: 25 PFIC patients, 25 healthy children and 25 Biliary Atresia patients were considered as case and two control groups respectively. Blood samples were obtained and Liver function tests (LFTs) were measured. After RNA extraction and cDNA synthesis, quantitative PCR was performed using specific primers for miR-19b and miR-let7b. The U6 gene is used as an internal control.
RESULTS: qPCR on PFIC patients\' samples demonstrated that the miR-19b and the miR-let7b expression were significantly decreased in patients compared to the control groups, with a p-value<0.0001 and p-value=0.0006 receptively.
CONCLUSIONS: In conclusion, circulating micro-RNA like miR-19b and miR-let7b have a potential opportunity to be a non-invasive diagnostic marker or therapeutic target for PFIC in the future.
方法:25名PFIC患者,25例健康儿童和25例胆道闭锁患者分别作为病例组和两个对照组。获得血液样品并测量肝功能测试(LFTs)。RNA提取和cDNA合成后,使用miR-19b和miR-let7b的特异性引物进行定量PCR。U6基因用作内部对照。
结果:对PFIC患者\'样本的qPCR表明,与对照组相比,患者的miR-19b和miR-let7b表达显着降低,p值<0.0001,p值=0.0006。
结论:结论:循环微小RNA,如miR-19b和miR-let7b,未来有可能成为PFIC的非侵入性诊断标记或治疗靶点.